• Hangzhou Diagens Biotechnology granted 778,962 share awards to 23 employees on October 20, 2026, under its 2026 share incentive scheme.
• The grants comprise 238,300 options for 11 employees and 540,662 restricted share units for 23 employees.
• Vesting periods range from five to 48 months, subject to continued employment or service, annual appraisals and conduct conditions.
• Options have a 10-year exercise period from the grant date.
• Newly issued H shares will satisfy the awards, leaving 8,108,958 H shares available for future grants.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou Diagens Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261020-12377448), on October 20, 2026, and is solely responsible for the information contained therein.